Strategies to Isolate and Expand Myeloma Specific T-cells Using Autologous B Cells as Antigen Presenting Cell B-APC
18 Years
N/A
Both
Multiple Myeloma and Plasma Cell Neoplasm
Trial Information
Strategies to Isolate and Expand Myeloma Specific T-cells Using Autologous B Cells as Antigen Presenting Cell B-APC
OBJECTIVES:
Primary
- To evaluate the feasibility of expanding myeloma-specific T cells using autologous ex
vivo expanded B cells loaded with myeloma antigens as antigen-presenting cells (B-APCs)
in peripheral blood and bone marrow samples from patients with multiple myeloma.
Secondary
- To examine the feasibility of selecting and expanding myeloma-specific T cells ex vivo
using interferon γ release and CD3/CD28 stimulation.
OUTLINE: Peripheral blood and bone marrow samples are collected periodically for laboratory
studies. Samples are analyzed to assess the feasibility of expanding autologous B cells ex
vivo using CD40L and IL-4; the antigen-presenting phenotype of autologous B-cell
antigen-presenting cells (B-APCs) using flow cytometry; and the antigen-presenting function
of B-APCs using ELISPOT and chromium-release assay. Myeloma-specific interferon γ secreting
T cells are isolated and selected using Miltenyi beads. The selected myeloma-specific T
cells are expanded ex vivo using anti CD3/CD28 beads.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Diagnosis of multiple myeloma
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
Percentage of myeloma-specific T cells ex vivo expanded using flow cytometry
Outcome Time Frame:
Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
Safety Issue:
No
Principal Investigator
Zaid Al-Kadhimi, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Barbara Ann Karmanos Cancer Institute
Authority:
United States: Food and Drug Administration
Study ID:
CDR0000597015
NCT ID:
NCT00897910
Start Date:
April 2008
Completion Date:
Related Keywords:
- Multiple Myeloma and Plasma Cell Neoplasm
- stage I multiple myeloma
- stage II multiple myeloma
- stage III multiple myeloma
- refractory multiple myeloma
- Neoplasms
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Plasmacytoma
Name | Location |
|---|---|
| Barbara Ann Karmanos Cancer Institute | Detroit, Michigan 48201 |
